Samjin Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samjin Pharmaceutical makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.
It is listed on KOSPI, South Korea's main stock exchange. The filing covers a broad product and services portfolio alongside active research and development activity, suggesting the business spans both established drug lines and pipeline work.
Summary is AI-generated and may contain errors · figures from DART filings
Samjin Pharmaceutical in five facts
What does Samjin Pharmaceutical do?
Samjin Pharmaceutical makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.
Where is Samjin Pharmaceutical listed and in which sector?
Samjin Pharmaceutical (Korean name: 삼진제약) trades under KRX code 005500 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samjin Pharmaceutical?
Its market capitalisation was US$192.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samjin Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Samjin Pharmaceutical reported revenue of US$233.3M, operating profit of US$20.2M and net income of US$18.2M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 0.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 2
- Report on large shareholdings (5% rule) (standard)Sep 2
- Cash/in-kind dividend decision
Samjin Pharmaceutical declared a cash dividend of US$0.55 per share.
Dividend · Feb 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Feb 2